Efficacy and Safety of Apremilast in Psoriasis

Ghurki Trust and Teaching Hospital

Status and phase: Completed; Phase 4

Conditions: Psoriasis

Treatments: Drug: Apremilast 30mg

Study type: Interventional

Funder types: Other

Identifiers

NCT06032858

D6

Details and patient eligibility

About

Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Enrollment: 30 patients

Sex: All

Ages: 18 to 59 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosed patients of chronic plaque psoriasis
• patients applicant for oral or parenteral treatments and for light therapy
• patients not responding to topical treatments

Exclusion criteria

• Patients who show hypersensitive reactions to apremilast to any of its inactive component
• Pregnancy
• Lactating mothers

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Apremilast 30 mg twice daily

Experimental group

Treatment:

Drug: Apremilast 30mg